BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Verve Therapeutics, Inc. (Nasdaq - VERV)

Under the terms of the Merger Agreement, Verve will be acquired by Eli Lilly and Company (“Lilly”) (NYSE - LLY). Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion). The investigation concerns whether the Verve Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/verve-therapeutics-inc-nasdaq-verv/,.

Sage Therapeutics, Inc. (Nasdaq - SAGE)

Under the terms of the agreement, Sage will be acquired by Supernus Pharmaceuticals, Inc. (Nasdaq - SUPN). Supernus will commence a tender offer to acquire all of the outstanding shares of Sage for a purchase price of $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total possible consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The investigation concerns whether the Sage Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/sage-therapeutics-inc-nasdaq-sage/.

Cantaloupe, Inc. (Nasdaq - CTLP)

Under the terms of the Merger Agreement, Cantaloupe will be acquired by 365 Retail Markets, LLC (“365”) for $11.20 per share in cash. The investigation concerns whether the Cantaloupe Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/cantaloupe-inc-nasdaq-ctlp/.

Volato Group, Inc. (NYSE American - SOAR)

Under the terms of the agreement, Volato Group will merge with M2i Global, Inc. (“M2i Global”) (OTC - MTWO). M2i Global will receive common shares of Volato Group stock such that M2i Global will own approximately 90% of the total shares of common stock of Volato. The investigation concerns whether the Volato Group Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company’s shareholders in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/volato-group-inc-nyse-american-soar/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.